nodes	percent_of_prediction	percent_of_DWPC	metapath
Naloxone—ABCB1—kidney cancer	0.202	1	CbGaD
Naloxone—ABCB1—Temsirolimus—kidney cancer	0.045	0.0955	CbGbCtD
Naloxone—CYP3A4—Everolimus—kidney cancer	0.0399	0.0847	CbGbCtD
Naloxone—CYP2C8—Pazopanib—kidney cancer	0.0349	0.0741	CbGbCtD
Naloxone—ALB—Erlotinib—kidney cancer	0.0322	0.0684	CbGbCtD
Naloxone—CYP3A4—Temsirolimus—kidney cancer	0.0269	0.0572	CbGbCtD
Naloxone—CYP2C8—Erlotinib—kidney cancer	0.0249	0.0529	CbGbCtD
Naloxone—ABCB1—Pazopanib—kidney cancer	0.0236	0.0502	CbGbCtD
Naloxone—CYP2C8—Paclitaxel—kidney cancer	0.0228	0.0484	CbGbCtD
Naloxone—ABCB1—Dactinomycin—kidney cancer	0.0216	0.0459	CbGbCtD
Naloxone—CYP2C8—Sorafenib—kidney cancer	0.0202	0.043	CbGbCtD
Naloxone—ABCB1—Gemcitabine—kidney cancer	0.0171	0.0363	CbGbCtD
Naloxone—ABCB1—Erlotinib—kidney cancer	0.0169	0.0358	CbGbCtD
Naloxone—ABCB1—Paclitaxel—kidney cancer	0.0154	0.0328	CbGbCtD
Naloxone—CYP3A4—Pazopanib—kidney cancer	0.0142	0.0301	CbGbCtD
Naloxone—ABCB1—Sorafenib—kidney cancer	0.0137	0.0291	CbGbCtD
Naloxone—ABCB1—Vinblastine—kidney cancer	0.0135	0.0287	CbGbCtD
Naloxone—ABCB1—Vincristine—kidney cancer	0.0133	0.0283	CbGbCtD
Naloxone—ABCB1—Sunitinib—kidney cancer	0.0111	0.0236	CbGbCtD
Naloxone—CYP3A4—Erlotinib—kidney cancer	0.0101	0.0214	CbGbCtD
Naloxone—CYP3A4—Paclitaxel—kidney cancer	0.00925	0.0196	CbGbCtD
Naloxone—ABCB1—Doxorubicin—kidney cancer	0.00832	0.0177	CbGbCtD
Naloxone—CYP3A4—Sorafenib—kidney cancer	0.00821	0.0174	CbGbCtD
Naloxone—CYP3A4—Vinblastine—kidney cancer	0.00811	0.0172	CbGbCtD
Naloxone—CYP3A4—Vincristine—kidney cancer	0.00797	0.0169	CbGbCtD
Naloxone—CYP3A4—Sunitinib—kidney cancer	0.00665	0.0141	CbGbCtD
Naloxone—CYP3A4—Doxorubicin—kidney cancer	0.00498	0.0106	CbGbCtD
Naloxone—CREB1—nephron tubule—kidney cancer	0.00182	0.098	CbGeAlD
Naloxone—CREB1—renal system—kidney cancer	0.00166	0.0891	CbGeAlD
Naloxone—CREB1—kidney—kidney cancer	0.0016	0.0861	CbGeAlD
Naloxone—CREB1—cortex of kidney—kidney cancer	0.00156	0.0838	CbGeAlD
Naloxone—CYP3A4—urine—kidney cancer	0.00149	0.0799	CbGeAlD
Naloxone—CREB1—gonad—kidney cancer	0.00149	0.0799	CbGeAlD
Naloxone—OPRD1—renal system—kidney cancer	0.00131	0.0704	CbGeAlD
Naloxone—OPRD1—kidney—kidney cancer	0.00127	0.0681	CbGeAlD
Naloxone—SLCO1A2—renal system—kidney cancer	0.000769	0.0413	CbGeAlD
Naloxone—SLCO1A2—kidney—kidney cancer	0.000744	0.04	CbGeAlD
Naloxone—ESR1—renal system—kidney cancer	0.000652	0.0351	CbGeAlD
Naloxone—ESR1—kidney—kidney cancer	0.000631	0.0339	CbGeAlD
Naloxone—ESR1—gonad—kidney cancer	0.000585	0.0314	CbGeAlD
Naloxone—Chills—Everolimus—kidney cancer	0.000553	0.00419	CcSEcCtD
Naloxone—Nervous system disorder—Pazopanib—kidney cancer	0.000544	0.00412	CcSEcCtD
Naloxone—Mental disorder—Everolimus—kidney cancer	0.00054	0.00409	CcSEcCtD
Naloxone—Skin disorder—Pazopanib—kidney cancer	0.000538	0.00408	CcSEcCtD
Naloxone—CYP2C8—renal system—kidney cancer	0.000537	0.0289	CbGeAlD
Naloxone—Hyperhidrosis—Pazopanib—kidney cancer	0.000536	0.00406	CcSEcCtD
Naloxone—Mediastinal disorder—Erlotinib—kidney cancer	0.000536	0.00406	CcSEcCtD
Naloxone—Hot flush—Paclitaxel—kidney cancer	0.000534	0.00405	CcSEcCtD
Naloxone—Chills—Erlotinib—kidney cancer	0.000533	0.00404	CcSEcCtD
Naloxone—Menopausal symptoms—Paclitaxel—kidney cancer	0.00053	0.00401	CcSEcCtD
Naloxone—Dyspnoea—Temsirolimus—kidney cancer	0.000525	0.00397	CcSEcCtD
Naloxone—Mental disorder—Erlotinib—kidney cancer	0.000521	0.00394	CcSEcCtD
Naloxone—CYP2C8—kidney—kidney cancer	0.00052	0.0279	CbGeAlD
Naloxone—Gastrointestinal disorder—Temsirolimus—kidney cancer	0.000508	0.00385	CcSEcCtD
Naloxone—Pain—Temsirolimus—kidney cancer	0.000503	0.00381	CcSEcCtD
Naloxone—Tremor—Everolimus—kidney cancer	0.000502	0.00381	CcSEcCtD
Naloxone—Paraesthesia—Pazopanib—kidney cancer	0.000498	0.00377	CcSEcCtD
Naloxone—Flushing—Sorafenib—kidney cancer	0.000496	0.00376	CcSEcCtD
Naloxone—Cardiac disorder—Sorafenib—kidney cancer	0.000496	0.00376	CcSEcCtD
Naloxone—Dyspnoea—Pazopanib—kidney cancer	0.000494	0.00374	CcSEcCtD
Naloxone—Agitation—Everolimus—kidney cancer	0.000493	0.00373	CcSEcCtD
Naloxone—Angiopathy—Sorafenib—kidney cancer	0.000485	0.00368	CcSEcCtD
Naloxone—Depression—Vincristine—kidney cancer	0.000483	0.00366	CcSEcCtD
Naloxone—Mediastinal disorder—Sorafenib—kidney cancer	0.000482	0.00365	CcSEcCtD
Naloxone—Gastrointestinal disorder—Pazopanib—kidney cancer	0.000479	0.00363	CcSEcCtD
Naloxone—Cardiac disorder—Sunitinib—kidney cancer	0.000478	0.00362	CcSEcCtD
Naloxone—Flushing—Sunitinib—kidney cancer	0.000478	0.00362	CcSEcCtD
Naloxone—Cardiac arrest—Paclitaxel—kidney cancer	0.000475	0.0036	CcSEcCtD
Naloxone—Pain—Pazopanib—kidney cancer	0.000474	0.00359	CcSEcCtD
Naloxone—Mental disorder—Sorafenib—kidney cancer	0.000469	0.00355	CcSEcCtD
Naloxone—Angiopathy—Sunitinib—kidney cancer	0.000467	0.00354	CcSEcCtD
Naloxone—Convulsion—Vinblastine—kidney cancer	0.000466	0.00353	CcSEcCtD
Naloxone—Abdominal pain—Temsirolimus—kidney cancer	0.000465	0.00352	CcSEcCtD
Naloxone—Body temperature increased—Temsirolimus—kidney cancer	0.000465	0.00352	CcSEcCtD
Naloxone—Hypertension—Vinblastine—kidney cancer	0.000465	0.00352	CcSEcCtD
Naloxone—Sweating—Vincristine—kidney cancer	0.000465	0.00352	CcSEcCtD
Naloxone—Convulsion—Everolimus—kidney cancer	0.000465	0.00352	CcSEcCtD
Naloxone—Mediastinal disorder—Sunitinib—kidney cancer	0.000464	0.00351	CcSEcCtD
Naloxone—Hypertension—Everolimus—kidney cancer	0.000463	0.00351	CcSEcCtD
Naloxone—Chills—Sunitinib—kidney cancer	0.000462	0.0035	CcSEcCtD
Naloxone—Unspecified disorder of skin and subcutaneous tissue—Everolimus—kidney cancer	0.000453	0.00343	CcSEcCtD
Naloxone—Flushing—Dactinomycin—kidney cancer	0.000452	0.00342	CcSEcCtD
Naloxone—Mental disorder—Sunitinib—kidney cancer	0.000451	0.00341	CcSEcCtD
Naloxone—Nasopharyngitis—Paclitaxel—kidney cancer	0.000447	0.00338	CcSEcCtD
Naloxone—Sweating—Gemcitabine—kidney cancer	0.000441	0.00334	CcSEcCtD
Naloxone—Hot flush—Capecitabine—kidney cancer	0.000438	0.00332	CcSEcCtD
Naloxone—Abdominal pain—Pazopanib—kidney cancer	0.000438	0.00332	CcSEcCtD
Naloxone—Unspecified disorder of skin and subcutaneous tissue—Erlotinib—kidney cancer	0.000438	0.00331	CcSEcCtD
Naloxone—Chills—Dactinomycin—kidney cancer	0.000437	0.00331	CcSEcCtD
Naloxone—Menopausal symptoms—Capecitabine—kidney cancer	0.000435	0.00329	CcSEcCtD
Naloxone—Hallucination—Vincristine—kidney cancer	0.000433	0.00328	CcSEcCtD
Naloxone—Nervous system disorder—Everolimus—kidney cancer	0.000429	0.00325	CcSEcCtD
Naloxone—Tachycardia—Everolimus—kidney cancer	0.000427	0.00324	CcSEcCtD
Naloxone—Skin disorder—Everolimus—kidney cancer	0.000425	0.00322	CcSEcCtD
Naloxone—Hyperhidrosis—Everolimus—kidney cancer	0.000423	0.00321	CcSEcCtD
Naloxone—Asthenia—Temsirolimus—kidney cancer	0.000422	0.0032	CcSEcCtD
Naloxone—Nervous system disorder—Erlotinib—kidney cancer	0.000414	0.00314	CcSEcCtD
Naloxone—Skin disorder—Erlotinib—kidney cancer	0.00041	0.00311	CcSEcCtD
Naloxone—Cardiac disorder—Vincristine—kidney cancer	0.000404	0.00306	CcSEcCtD
Naloxone—Diarrhoea—Temsirolimus—kidney cancer	0.000403	0.00305	CcSEcCtD
Naloxone—Hypertension—Sorafenib—kidney cancer	0.000402	0.00304	CcSEcCtD
Naloxone—Asthenia—Pazopanib—kidney cancer	0.000398	0.00301	CcSEcCtD
Naloxone—Angiopathy—Vincristine—kidney cancer	0.000395	0.00299	CcSEcCtD
Naloxone—Paraesthesia—Vinblastine—kidney cancer	0.000395	0.00299	CcSEcCtD
Naloxone—Unspecified disorder of skin and subcutaneous tissue—Sorafenib—kidney cancer	0.000394	0.00298	CcSEcCtD
Naloxone—Paraesthesia—Everolimus—kidney cancer	0.000393	0.00298	CcSEcCtD
Naloxone—Mediastinal disorder—Vincristine—kidney cancer	0.000392	0.00297	CcSEcCtD
Naloxone—Irritability—Capecitabine—kidney cancer	0.000391	0.00296	CcSEcCtD
Naloxone—Dyspnoea—Everolimus—kidney cancer	0.00039	0.00296	CcSEcCtD
Naloxone—Cardiac arrest—Capecitabine—kidney cancer	0.00039	0.00295	CcSEcCtD
Naloxone—Convulsion—Sunitinib—kidney cancer	0.000388	0.00294	CcSEcCtD
Naloxone—Hypertension—Sunitinib—kidney cancer	0.000387	0.00293	CcSEcCtD
Naloxone—Depression—Paclitaxel—kidney cancer	0.000384	0.00291	CcSEcCtD
Naloxone—Cardiac disorder—Gemcitabine—kidney cancer	0.000383	0.0029	CcSEcCtD
Naloxone—Mental disorder—Vincristine—kidney cancer	0.000381	0.00289	CcSEcCtD
Naloxone—Diarrhoea—Pazopanib—kidney cancer	0.000379	0.00287	CcSEcCtD
Naloxone—Unspecified disorder of skin and subcutaneous tissue—Sunitinib—kidney cancer	0.000379	0.00287	CcSEcCtD
Naloxone—Gastrointestinal disorder—Everolimus—kidney cancer	0.000378	0.00286	CcSEcCtD
Naloxone—Dyspnoea—Erlotinib—kidney cancer	0.000377	0.00285	CcSEcCtD
Naloxone—Pain—Vinblastine—kidney cancer	0.000376	0.00285	CcSEcCtD
Naloxone—Angiopathy—Gemcitabine—kidney cancer	0.000375	0.00284	CcSEcCtD
Naloxone—Pain—Everolimus—kidney cancer	0.000374	0.00284	CcSEcCtD
Naloxone—Vomiting—Temsirolimus—kidney cancer	0.000374	0.00283	CcSEcCtD
Naloxone—Nervous system disorder—Sorafenib—kidney cancer	0.000373	0.00282	CcSEcCtD
Naloxone—Mediastinal disorder—Gemcitabine—kidney cancer	0.000372	0.00282	CcSEcCtD
Naloxone—Chills—Gemcitabine—kidney cancer	0.00037	0.00281	CcSEcCtD
Naloxone—Skin disorder—Sorafenib—kidney cancer	0.000369	0.0028	CcSEcCtD
Naloxone—Nasopharyngitis—Capecitabine—kidney cancer	0.000367	0.00278	CcSEcCtD
Naloxone—Gastrointestinal disorder—Erlotinib—kidney cancer	0.000365	0.00276	CcSEcCtD
Naloxone—Ventricular tachycardia—Doxorubicin—kidney cancer	0.000364	0.00276	CcSEcCtD
Naloxone—CYP3A4—renal system—kidney cancer	0.000364	0.0196	CbGeAlD
Naloxone—Injection site reaction—Doxorubicin—kidney cancer	0.000362	0.00274	CcSEcCtD
Naloxone—Pain—Erlotinib—kidney cancer	0.000361	0.00274	CcSEcCtD
Naloxone—Nervous system disorder—Sunitinib—kidney cancer	0.000359	0.00272	CcSEcCtD
Naloxone—Skin disorder—Sunitinib—kidney cancer	0.000355	0.00269	CcSEcCtD
Naloxone—Vomiting—Pazopanib—kidney cancer	0.000352	0.00267	CcSEcCtD
Naloxone—CYP3A4—kidney—kidney cancer	0.000352	0.0189	CbGeAlD
Naloxone—Nausea—Temsirolimus—kidney cancer	0.00035	0.00265	CcSEcCtD
Naloxone—Agitation—Vincristine—kidney cancer	0.000348	0.00264	CcSEcCtD
Naloxone—Abdominal pain—Vinblastine—kidney cancer	0.000347	0.00263	CcSEcCtD
Naloxone—Hydromorphone—PTGS1—kidney cancer	0.000346	0.388	CrCbGaD
Naloxone—Body temperature increased—Everolimus—kidney cancer	0.000346	0.00262	CcSEcCtD
Naloxone—Abdominal pain—Everolimus—kidney cancer	0.000346	0.00262	CcSEcCtD
Naloxone—Dyspnoea—Sorafenib—kidney cancer	0.000339	0.00257	CcSEcCtD
Naloxone—Abdominal pain—Erlotinib—kidney cancer	0.000334	0.00253	CcSEcCtD
Naloxone—Body temperature increased—Erlotinib—kidney cancer	0.000334	0.00253	CcSEcCtD
Naloxone—Coma—Doxorubicin—kidney cancer	0.000333	0.00252	CcSEcCtD
Naloxone—Nausea—Pazopanib—kidney cancer	0.000329	0.00249	CcSEcCtD
Naloxone—Paraesthesia—Sunitinib—kidney cancer	0.000328	0.00249	CcSEcCtD
Naloxone—Convulsion—Vincristine—kidney cancer	0.000328	0.00249	CcSEcCtD
Naloxone—Gastrointestinal disorder—Sorafenib—kidney cancer	0.000328	0.00248	CcSEcCtD
Naloxone—Hypertension—Vincristine—kidney cancer	0.000327	0.00248	CcSEcCtD
Naloxone—Dyspnoea—Sunitinib—kidney cancer	0.000326	0.00247	CcSEcCtD
Naloxone—Pain—Sorafenib—kidney cancer	0.000325	0.00246	CcSEcCtD
Naloxone—Pulmonary oedema—Doxorubicin—kidney cancer	0.000324	0.00246	CcSEcCtD
Naloxone—Flushing—Paclitaxel—kidney cancer	0.000321	0.00243	CcSEcCtD
Naloxone—Cardiac disorder—Paclitaxel—kidney cancer	0.000321	0.00243	CcSEcCtD
Naloxone—Gastrointestinal disorder—Sunitinib—kidney cancer	0.000316	0.00239	CcSEcCtD
Naloxone—Asthenia—Vinblastine—kidney cancer	0.000315	0.00239	CcSEcCtD
Naloxone—Depression—Capecitabine—kidney cancer	0.000315	0.00239	CcSEcCtD
Naloxone—Asthenia—Everolimus—kidney cancer	0.000314	0.00238	CcSEcCtD
Naloxone—Angiopathy—Paclitaxel—kidney cancer	0.000314	0.00238	CcSEcCtD
Naloxone—Pain—Sunitinib—kidney cancer	0.000313	0.00237	CcSEcCtD
Naloxone—Mediastinal disorder—Paclitaxel—kidney cancer	0.000312	0.00236	CcSEcCtD
Naloxone—Hypertension—Gemcitabine—kidney cancer	0.00031	0.00235	CcSEcCtD
Naloxone—Chills—Paclitaxel—kidney cancer	0.00031	0.00235	CcSEcCtD
Naloxone—Unspecified disorder of skin and subcutaneous tissue—Gemcitabine—kidney cancer	0.000304	0.0023	CcSEcCtD
Naloxone—Nervous system disorder—Vincristine—kidney cancer	0.000303	0.0023	CcSEcCtD
Naloxone—Asthenia—Erlotinib—kidney cancer	0.000303	0.0023	CcSEcCtD
Naloxone—Mental disorder—Paclitaxel—kidney cancer	0.000303	0.00229	CcSEcCtD
Naloxone—Diarrhoea—Vinblastine—kidney cancer	0.000301	0.00228	CcSEcCtD
Naloxone—Body temperature increased—Sorafenib—kidney cancer	0.0003	0.00228	CcSEcCtD
Naloxone—Abdominal pain—Sorafenib—kidney cancer	0.0003	0.00228	CcSEcCtD
Naloxone—Diarrhoea—Everolimus—kidney cancer	0.000299	0.00227	CcSEcCtD
Naloxone—Hyperhidrosis—Vincristine—kidney cancer	0.000299	0.00226	CcSEcCtD
Naloxone—Pain—Dactinomycin—kidney cancer	0.000296	0.00224	CcSEcCtD
Naloxone—Tension—Paclitaxel—kidney cancer	0.000295	0.00224	CcSEcCtD
Naloxone—Nervousness—Paclitaxel—kidney cancer	0.000292	0.00221	CcSEcCtD
Naloxone—Abdominal pain—Sunitinib—kidney cancer	0.000289	0.00219	CcSEcCtD
Naloxone—Body temperature increased—Sunitinib—kidney cancer	0.000289	0.00219	CcSEcCtD
Naloxone—Diarrhoea—Erlotinib—kidney cancer	0.000289	0.00219	CcSEcCtD
Naloxone—Nervous system disorder—Gemcitabine—kidney cancer	0.000288	0.00218	CcSEcCtD
Naloxone—Skin disorder—Gemcitabine—kidney cancer	0.000285	0.00216	CcSEcCtD
Naloxone—Hyperhidrosis—Gemcitabine—kidney cancer	0.000284	0.00215	CcSEcCtD
Naloxone—ABCB1—nephron tubule—kidney cancer	0.000283	0.0152	CbGeAlD
Naloxone—Hot flush—Doxorubicin—kidney cancer	0.000283	0.00214	CcSEcCtD
Naloxone—Tremor—Paclitaxel—kidney cancer	0.000282	0.00214	CcSEcCtD
Naloxone—Menopausal symptoms—Doxorubicin—kidney cancer	0.00028	0.00212	CcSEcCtD
Naloxone—Vomiting—Vinblastine—kidney cancer	0.000279	0.00212	CcSEcCtD
Naloxone—Vomiting—Everolimus—kidney cancer	0.000278	0.00211	CcSEcCtD
Naloxone—Paraesthesia—Vincristine—kidney cancer	0.000278	0.0021	CcSEcCtD
Naloxone—Agitation—Paclitaxel—kidney cancer	0.000277	0.00209	CcSEcCtD
Naloxone—Body temperature increased—Dactinomycin—kidney cancer	0.000274	0.00207	CcSEcCtD
Naloxone—Abdominal pain—Dactinomycin—kidney cancer	0.000274	0.00207	CcSEcCtD
Naloxone—Asthenia—Sorafenib—kidney cancer	0.000273	0.00206	CcSEcCtD
Naloxone—Vomiting—Erlotinib—kidney cancer	0.000269	0.00203	CcSEcCtD
Naloxone—Gastrointestinal disorder—Vincristine—kidney cancer	0.000267	0.00202	CcSEcCtD
Naloxone—Pain—Vincristine—kidney cancer	0.000264	0.002	CcSEcCtD
Naloxone—Paraesthesia—Gemcitabine—kidney cancer	0.000263	0.002	CcSEcCtD
Naloxone—Flushing—Capecitabine—kidney cancer	0.000263	0.00199	CcSEcCtD
Naloxone—Cardiac disorder—Capecitabine—kidney cancer	0.000263	0.00199	CcSEcCtD
Naloxone—Asthenia—Sunitinib—kidney cancer	0.000262	0.00199	CcSEcCtD
Naloxone—Dyspnoea—Gemcitabine—kidney cancer	0.000262	0.00198	CcSEcCtD
Naloxone—Nausea—Vinblastine—kidney cancer	0.000261	0.00198	CcSEcCtD
Naloxone—Convulsion—Paclitaxel—kidney cancer	0.000261	0.00197	CcSEcCtD
Naloxone—Nausea—Everolimus—kidney cancer	0.00026	0.00197	CcSEcCtD
Naloxone—Diarrhoea—Sorafenib—kidney cancer	0.00026	0.00197	CcSEcCtD
Naloxone—Hypertension—Paclitaxel—kidney cancer	0.00026	0.00197	CcSEcCtD
Naloxone—ABCB1—renal system—kidney cancer	0.000258	0.0138	CbGeAlD
Naloxone—Angiopathy—Capecitabine—kidney cancer	0.000257	0.00195	CcSEcCtD
Naloxone—Mediastinal disorder—Capecitabine—kidney cancer	0.000256	0.00194	CcSEcCtD
Naloxone—Chills—Capecitabine—kidney cancer	0.000255	0.00193	CcSEcCtD
Naloxone—Unspecified disorder of skin and subcutaneous tissue—Paclitaxel—kidney cancer	0.000254	0.00193	CcSEcCtD
Naloxone—Gastrointestinal disorder—Gemcitabine—kidney cancer	0.000253	0.00192	CcSEcCtD
Naloxone—Cardiac arrest—Doxorubicin—kidney cancer	0.000251	0.0019	CcSEcCtD
Naloxone—Pain—Gemcitabine—kidney cancer	0.000251	0.0019	CcSEcCtD
Naloxone—Nausea—Erlotinib—kidney cancer	0.000251	0.0019	CcSEcCtD
Naloxone—Diarrhoea—Sunitinib—kidney cancer	0.00025	0.00189	CcSEcCtD
Naloxone—ABCB1—kidney—kidney cancer	0.000249	0.0134	CbGeAlD
Naloxone—Mental disorder—Capecitabine—kidney cancer	0.000249	0.00188	CcSEcCtD
Naloxone—Asthenia—Dactinomycin—kidney cancer	0.000248	0.00188	CcSEcCtD
Naloxone—Abdominal pain—Vincristine—kidney cancer	0.000244	0.00185	CcSEcCtD
Naloxone—Body temperature increased—Vincristine—kidney cancer	0.000244	0.00185	CcSEcCtD
Naloxone—ABCB1—cortex of kidney—kidney cancer	0.000243	0.013	CbGeAlD
Naloxone—Vomiting—Sorafenib—kidney cancer	0.000242	0.00183	CcSEcCtD
Naloxone—Nervous system disorder—Paclitaxel—kidney cancer	0.000241	0.00182	CcSEcCtD
Naloxone—Tachycardia—Paclitaxel—kidney cancer	0.00024	0.00182	CcSEcCtD
Naloxone—Skin disorder—Paclitaxel—kidney cancer	0.000239	0.00181	CcSEcCtD
Naloxone—Hyperhidrosis—Paclitaxel—kidney cancer	0.000237	0.0018	CcSEcCtD
Naloxone—Diarrhoea—Dactinomycin—kidney cancer	0.000237	0.00179	CcSEcCtD
Naloxone—Nasopharyngitis—Doxorubicin—kidney cancer	0.000236	0.00179	CcSEcCtD
Naloxone—Vomiting—Sunitinib—kidney cancer	0.000232	0.00176	CcSEcCtD
Naloxone—Naltrexone—ABCB1—kidney cancer	0.000232	0.26	CrCbGaD
Naloxone—Body temperature increased—Gemcitabine—kidney cancer	0.000232	0.00176	CcSEcCtD
Naloxone—Tremor—Capecitabine—kidney cancer	0.000231	0.00175	CcSEcCtD
Naloxone—ABCB1—gonad—kidney cancer	0.000231	0.0124	CbGeAlD
Naloxone—Nausea—Sorafenib—kidney cancer	0.000226	0.00171	CcSEcCtD
Naloxone—Asthenia—Vincristine—kidney cancer	0.000222	0.00168	CcSEcCtD
Naloxone—Paraesthesia—Paclitaxel—kidney cancer	0.000221	0.00167	CcSEcCtD
Naloxone—Vomiting—Dactinomycin—kidney cancer	0.00022	0.00167	CcSEcCtD
Naloxone—Dyspnoea—Paclitaxel—kidney cancer	0.000219	0.00166	CcSEcCtD
Naloxone—Nausea—Sunitinib—kidney cancer	0.000217	0.00164	CcSEcCtD
Naloxone—Hypertension—Capecitabine—kidney cancer	0.000213	0.00162	CcSEcCtD
Naloxone—Gastrointestinal disorder—Paclitaxel—kidney cancer	0.000212	0.00161	CcSEcCtD
Naloxone—Diarrhoea—Vincristine—kidney cancer	0.000212	0.0016	CcSEcCtD
Naloxone—Asthenia—Gemcitabine—kidney cancer	0.00021	0.00159	CcSEcCtD
Naloxone—Pain—Paclitaxel—kidney cancer	0.00021	0.00159	CcSEcCtD
Naloxone—Unspecified disorder of skin and subcutaneous tissue—Capecitabine—kidney cancer	0.000209	0.00158	CcSEcCtD
Naloxone—Nausea—Dactinomycin—kidney cancer	0.000206	0.00156	CcSEcCtD
Naloxone—Diarrhoea—Gemcitabine—kidney cancer	0.000201	0.00152	CcSEcCtD
Naloxone—Nervous system disorder—Capecitabine—kidney cancer	0.000198	0.0015	CcSEcCtD
Naloxone—Tachycardia—Capecitabine—kidney cancer	0.000197	0.00149	CcSEcCtD
Naloxone—Vomiting—Vincristine—kidney cancer	0.000197	0.00149	CcSEcCtD
Naloxone—Skin disorder—Capecitabine—kidney cancer	0.000196	0.00148	CcSEcCtD
Naloxone—Sweating—Doxorubicin—kidney cancer	0.000195	0.00148	CcSEcCtD
Naloxone—Hyperhidrosis—Capecitabine—kidney cancer	0.000195	0.00148	CcSEcCtD
Naloxone—Body temperature increased—Paclitaxel—kidney cancer	0.000194	0.00147	CcSEcCtD
Naloxone—Abdominal pain—Paclitaxel—kidney cancer	0.000194	0.00147	CcSEcCtD
Naloxone—Vomiting—Gemcitabine—kidney cancer	0.000187	0.00141	CcSEcCtD
Naloxone—Nausea—Vincristine—kidney cancer	0.000184	0.00139	CcSEcCtD
Naloxone—Paraesthesia—Capecitabine—kidney cancer	0.000181	0.00137	CcSEcCtD
Naloxone—Dyspnoea—Capecitabine—kidney cancer	0.00018	0.00136	CcSEcCtD
Naloxone—Asthenia—Paclitaxel—kidney cancer	0.000176	0.00133	CcSEcCtD
Naloxone—Nausea—Gemcitabine—kidney cancer	0.000174	0.00132	CcSEcCtD
Naloxone—Gastrointestinal disorder—Capecitabine—kidney cancer	0.000174	0.00132	CcSEcCtD
Naloxone—Pain—Capecitabine—kidney cancer	0.000172	0.00131	CcSEcCtD
Naloxone—Buprenorphine—ABCB1—kidney cancer	0.000171	0.191	CrCbGaD
Naloxone—Flushing—Doxorubicin—kidney cancer	0.00017	0.00129	CcSEcCtD
Naloxone—Cardiac disorder—Doxorubicin—kidney cancer	0.00017	0.00129	CcSEcCtD
Naloxone—Diarrhoea—Paclitaxel—kidney cancer	0.000168	0.00127	CcSEcCtD
Naloxone—Angiopathy—Doxorubicin—kidney cancer	0.000166	0.00126	CcSEcCtD
Naloxone—Mediastinal disorder—Doxorubicin—kidney cancer	0.000165	0.00125	CcSEcCtD
Naloxone—Chills—Doxorubicin—kidney cancer	0.000164	0.00124	CcSEcCtD
Naloxone—Mental disorder—Doxorubicin—kidney cancer	0.00016	0.00121	CcSEcCtD
Naloxone—Abdominal pain—Capecitabine—kidney cancer	0.000159	0.00121	CcSEcCtD
Naloxone—Body temperature increased—Capecitabine—kidney cancer	0.000159	0.00121	CcSEcCtD
Naloxone—Tension—Doxorubicin—kidney cancer	0.000156	0.00118	CcSEcCtD
Naloxone—Vomiting—Paclitaxel—kidney cancer	0.000156	0.00118	CcSEcCtD
Naloxone—Nervousness—Doxorubicin—kidney cancer	0.000155	0.00117	CcSEcCtD
Naloxone—Agitation—Doxorubicin—kidney cancer	0.000146	0.00111	CcSEcCtD
Naloxone—Nausea—Paclitaxel—kidney cancer	0.000146	0.00111	CcSEcCtD
Naloxone—Asthenia—Capecitabine—kidney cancer	0.000145	0.0011	CcSEcCtD
Naloxone—Morphine—ABCB1—kidney cancer	0.000143	0.16	CrCbGaD
Naloxone—Convulsion—Doxorubicin—kidney cancer	0.000138	0.00104	CcSEcCtD
Naloxone—Diarrhoea—Capecitabine—kidney cancer	0.000138	0.00104	CcSEcCtD
Naloxone—Hypertension—Doxorubicin—kidney cancer	0.000137	0.00104	CcSEcCtD
Naloxone—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—kidney cancer	0.000135	0.00102	CcSEcCtD
Naloxone—Vomiting—Capecitabine—kidney cancer	0.000128	0.000971	CcSEcCtD
Naloxone—Nervous system disorder—Doxorubicin—kidney cancer	0.000127	0.000965	CcSEcCtD
Naloxone—Tachycardia—Doxorubicin—kidney cancer	0.000127	0.00096	CcSEcCtD
Naloxone—Skin disorder—Doxorubicin—kidney cancer	0.000126	0.000956	CcSEcCtD
Naloxone—Hyperhidrosis—Doxorubicin—kidney cancer	0.000126	0.000951	CcSEcCtD
Naloxone—Nausea—Capecitabine—kidney cancer	0.00012	0.000907	CcSEcCtD
Naloxone—Paraesthesia—Doxorubicin—kidney cancer	0.000117	0.000884	CcSEcCtD
Naloxone—Dyspnoea—Doxorubicin—kidney cancer	0.000116	0.000877	CcSEcCtD
Naloxone—Gastrointestinal disorder—Doxorubicin—kidney cancer	0.000112	0.00085	CcSEcCtD
Naloxone—Pain—Doxorubicin—kidney cancer	0.000111	0.000842	CcSEcCtD
Naloxone—Abdominal pain—Doxorubicin—kidney cancer	0.000103	0.000778	CcSEcCtD
Naloxone—Body temperature increased—Doxorubicin—kidney cancer	0.000103	0.000778	CcSEcCtD
Naloxone—Asthenia—Doxorubicin—kidney cancer	9.32e-05	0.000706	CcSEcCtD
Naloxone—Diarrhoea—Doxorubicin—kidney cancer	8.89e-05	0.000673	CcSEcCtD
Naloxone—Vomiting—Doxorubicin—kidney cancer	8.26e-05	0.000626	CcSEcCtD
Naloxone—Nausea—Doxorubicin—kidney cancer	7.72e-05	0.000585	CcSEcCtD
Naloxone—CYP3A4—Metabolism—GPC3—kidney cancer	1.01e-05	5.76e-05	CbGpPWpGaD
Naloxone—SLCO1A2—Metabolism of lipids and lipoproteins—PIK3CA—kidney cancer	1.01e-05	5.76e-05	CbGpPWpGaD
Naloxone—ALB—Metabolism of lipids and lipoproteins—POMC—kidney cancer	1.01e-05	5.73e-05	CbGpPWpGaD
Naloxone—ABCB1—Integrated Pancreatic Cancer Pathway—TP53—kidney cancer	1e-05	5.71e-05	CbGpPWpGaD
Naloxone—CYP2C8—Metabolism—GSTT1—kidney cancer	1e-05	5.7e-05	CbGpPWpGaD
Naloxone—CYP2C8—Metabolism—ACHE—kidney cancer	1e-05	5.7e-05	CbGpPWpGaD
Naloxone—ALB—Metabolism—ACHE—kidney cancer	9.95e-06	5.67e-05	CbGpPWpGaD
Naloxone—ALB—Metabolism—GSTT1—kidney cancer	9.95e-06	5.67e-05	CbGpPWpGaD
Naloxone—CREB1—Signaling Pathways—KIT—kidney cancer	9.95e-06	5.67e-05	CbGpPWpGaD
Naloxone—CREB1—Signaling Pathways—APC—kidney cancer	9.95e-06	5.67e-05	CbGpPWpGaD
Naloxone—OPRD1—Signaling Pathways—APC—kidney cancer	9.92e-06	5.65e-05	CbGpPWpGaD
Naloxone—OPRD1—Signaling Pathways—KIT—kidney cancer	9.92e-06	5.65e-05	CbGpPWpGaD
Naloxone—OPRK1—Signaling Pathways—HIF1A—kidney cancer	9.87e-06	5.63e-05	CbGpPWpGaD
Naloxone—OPRK1—Signaling Pathways—TSC2—kidney cancer	9.85e-06	5.61e-05	CbGpPWpGaD
Naloxone—CYP3A4—Metabolism—CA2—kidney cancer	9.84e-06	5.6e-05	CbGpPWpGaD
Naloxone—OPRM1—Signaling by GPCR—RAF1—kidney cancer	9.77e-06	5.57e-05	CbGpPWpGaD
Naloxone—CREB1—Disease—CTNNB1—kidney cancer	9.66e-06	5.5e-05	CbGpPWpGaD
Naloxone—OPRM1—GPCR downstream signaling—IL2—kidney cancer	9.64e-06	5.5e-05	CbGpPWpGaD
Naloxone—CYP3A4—Metabolism—ALAD—kidney cancer	9.59e-06	5.46e-05	CbGpPWpGaD
Naloxone—ABCB1—Metabolism—ITPR2—kidney cancer	9.56e-06	5.45e-05	CbGpPWpGaD
Naloxone—CREB1—Signaling by GPCR—MAPK3—kidney cancer	9.53e-06	5.43e-05	CbGpPWpGaD
Naloxone—OPRD1—Signaling by GPCR—MAPK3—kidney cancer	9.5e-06	5.41e-05	CbGpPWpGaD
Naloxone—CYP2C8—Metabolism—SCARB1—kidney cancer	9.48e-06	5.4e-05	CbGpPWpGaD
Naloxone—CREB1—Signaling Pathways—POMC—kidney cancer	9.47e-06	5.4e-05	CbGpPWpGaD
Naloxone—OPRD1—Signaling Pathways—POMC—kidney cancer	9.44e-06	5.38e-05	CbGpPWpGaD
Naloxone—OPRK1—Signaling Pathways—KDR—kidney cancer	9.44e-06	5.38e-05	CbGpPWpGaD
Naloxone—ALB—Metabolism—SCARB1—kidney cancer	9.42e-06	5.37e-05	CbGpPWpGaD
Naloxone—CREB1—Disease—PTEN—kidney cancer	9.41e-06	5.36e-05	CbGpPWpGaD
Naloxone—CYP2C8—Metabolism—PTGS1—kidney cancer	9.38e-06	5.35e-05	CbGpPWpGaD
Naloxone—CYP3A4—Metabolism—ST3GAL2—kidney cancer	9.36e-06	5.33e-05	CbGpPWpGaD
Naloxone—CREB1—Signaling Pathways—BRAF—kidney cancer	9.36e-06	5.33e-05	CbGpPWpGaD
Naloxone—ALB—Metabolism—PTGS1—kidney cancer	9.33e-06	5.31e-05	CbGpPWpGaD
Naloxone—OPRD1—Signaling Pathways—BRAF—kidney cancer	9.33e-06	5.31e-05	CbGpPWpGaD
Naloxone—ESR1—Signaling Pathways—IGF2—kidney cancer	9.3e-06	5.3e-05	CbGpPWpGaD
Naloxone—ESR1—Signaling Pathways—CDKN2B—kidney cancer	9.26e-06	5.27e-05	CbGpPWpGaD
Naloxone—CYP2C8—Metabolism—PSMD7—kidney cancer	9.2e-06	5.24e-05	CbGpPWpGaD
Naloxone—SLCO1A2—Metabolism—POMC—kidney cancer	9.17e-06	5.23e-05	CbGpPWpGaD
Naloxone—ALB—Metabolism—PSMD7—kidney cancer	9.15e-06	5.21e-05	CbGpPWpGaD
Naloxone—CYP3A4—Metabolism—ALDH1A1—kidney cancer	9.14e-06	5.21e-05	CbGpPWpGaD
Naloxone—ALB—Hemostasis—RAF1—kidney cancer	9.11e-06	5.19e-05	CbGpPWpGaD
Naloxone—CREB1—Signaling by GPCR—MAPK1—kidney cancer	9.07e-06	5.17e-05	CbGpPWpGaD
Naloxone—OPRD1—Signaling by GPCR—MAPK1—kidney cancer	9.04e-06	5.15e-05	CbGpPWpGaD
Naloxone—ESR1—Signaling Pathways—IGF1R—kidney cancer	8.99e-06	5.12e-05	CbGpPWpGaD
Naloxone—CYP3A4—Metabolism—PGK1—kidney cancer	8.77e-06	5e-05	CbGpPWpGaD
Naloxone—CYP3A4—Metabolism—SLC5A3—kidney cancer	8.77e-06	5e-05	CbGpPWpGaD
Naloxone—OPRM1—Signaling by GPCR—IL2—kidney cancer	8.76e-06	4.99e-05	CbGpPWpGaD
Naloxone—ABCB1—Metabolism—GSTT1—kidney cancer	8.72e-06	4.97e-05	CbGpPWpGaD
Naloxone—ABCB1—Metabolism—ACHE—kidney cancer	8.72e-06	4.97e-05	CbGpPWpGaD
Naloxone—CYP2C8—Metabolism—BCHE—kidney cancer	8.72e-06	4.97e-05	CbGpPWpGaD
Naloxone—CREB1—Immune System—MAPK3—kidney cancer	8.71e-06	4.96e-05	CbGpPWpGaD
Naloxone—OPRK1—Signaling Pathways—APC—kidney cancer	8.7e-06	4.96e-05	CbGpPWpGaD
Naloxone—OPRK1—Signaling Pathways—KIT—kidney cancer	8.7e-06	4.96e-05	CbGpPWpGaD
Naloxone—ALB—Metabolism—BCHE—kidney cancer	8.67e-06	4.94e-05	CbGpPWpGaD
Naloxone—OPRD1—GPCR downstream signaling—PIK3CA—kidney cancer	8.64e-06	4.92e-05	CbGpPWpGaD
Naloxone—CYP2C8—Metabolism—SLC5A5—kidney cancer	8.61e-06	4.91e-05	CbGpPWpGaD
Naloxone—CYP3A4—Metabolism—LDHB—kidney cancer	8.6e-06	4.9e-05	CbGpPWpGaD
Naloxone—CREB1—Signaling by GPCR—KRAS—kidney cancer	8.57e-06	4.88e-05	CbGpPWpGaD
Naloxone—ALB—Metabolism—SLC5A5—kidney cancer	8.57e-06	4.88e-05	CbGpPWpGaD
Naloxone—OPRD1—Signaling by GPCR—KRAS—kidney cancer	8.54e-06	4.87e-05	CbGpPWpGaD
Naloxone—OPRM1—Signaling Pathways—HIF1A—kidney cancer	8.35e-06	4.76e-05	CbGpPWpGaD
Naloxone—OPRK1—Signaling by GPCR—MAPK3—kidney cancer	8.33e-06	4.75e-05	CbGpPWpGaD
Naloxone—OPRM1—Signaling Pathways—TSC2—kidney cancer	8.32e-06	4.74e-05	CbGpPWpGaD
Naloxone—CYP2C8—Metabolism—SLC2A1—kidney cancer	8.32e-06	4.74e-05	CbGpPWpGaD
Naloxone—CREB1—Immune System—MAPK1—kidney cancer	8.29e-06	4.72e-05	CbGpPWpGaD
Naloxone—OPRK1—Signaling Pathways—POMC—kidney cancer	8.28e-06	4.72e-05	CbGpPWpGaD
Naloxone—ALB—Metabolism—SLC2A1—kidney cancer	8.27e-06	4.71e-05	CbGpPWpGaD
Naloxone—ABCB1—Metabolism—SCARB1—kidney cancer	8.26e-06	4.7e-05	CbGpPWpGaD
Naloxone—OPRK1—Signaling Pathways—BRAF—kidney cancer	8.18e-06	4.66e-05	CbGpPWpGaD
Naloxone—ABCB1—Metabolism—PTGS1—kidney cancer	8.17e-06	4.66e-05	CbGpPWpGaD
Naloxone—ALB—Hemostasis—IL2—kidney cancer	8.17e-06	4.66e-05	CbGpPWpGaD
Naloxone—CYP2C8—Metabolism of lipids and lipoproteins—PTGS2—kidney cancer	8.07e-06	4.6e-05	CbGpPWpGaD
Naloxone—CREB1—Disease—MAPK3—kidney cancer	8.04e-06	4.58e-05	CbGpPWpGaD
Naloxone—ALB—Metabolism of lipids and lipoproteins—PTGS2—kidney cancer	8.03e-06	4.57e-05	CbGpPWpGaD
Naloxone—ABCB1—Metabolism—PSMD7—kidney cancer	8.01e-06	4.57e-05	CbGpPWpGaD
Naloxone—OPRM1—Signaling Pathways—KDR—kidney cancer	7.98e-06	4.55e-05	CbGpPWpGaD
Naloxone—OPRK1—Signaling by GPCR—MAPK1—kidney cancer	7.93e-06	4.52e-05	CbGpPWpGaD
Naloxone—ALB—Transmembrane transport of small molecules—RAF1—kidney cancer	7.89e-06	4.5e-05	CbGpPWpGaD
Naloxone—CREB1—Signaling by GPCR—PIK3CA—kidney cancer	7.87e-06	4.48e-05	CbGpPWpGaD
Naloxone—OPRD1—Signaling by GPCR—PIK3CA—kidney cancer	7.84e-06	4.47e-05	CbGpPWpGaD
Naloxone—CREB1—Immune System—KRAS—kidney cancer	7.83e-06	4.46e-05	CbGpPWpGaD
Naloxone—CREB1—Disease—MYC—kidney cancer	7.82e-06	4.46e-05	CbGpPWpGaD
Naloxone—CREB1—Signaling Pathways—RAF1—kidney cancer	7.81e-06	4.45e-05	CbGpPWpGaD
Naloxone—OPRD1—Signaling Pathways—RAF1—kidney cancer	7.79e-06	4.44e-05	CbGpPWpGaD
Naloxone—CREB1—Signaling Pathways—RELA—kidney cancer	7.78e-06	4.43e-05	CbGpPWpGaD
Naloxone—OPRD1—Signaling Pathways—RELA—kidney cancer	7.75e-06	4.42e-05	CbGpPWpGaD
Naloxone—CREB1—Signaling Pathways—ERBB2—kidney cancer	7.73e-06	4.4e-05	CbGpPWpGaD
Naloxone—OPRD1—Signaling Pathways—ERBB2—kidney cancer	7.7e-06	4.39e-05	CbGpPWpGaD
Naloxone—CREB1—Disease—MAPK1—kidney cancer	7.65e-06	4.36e-05	CbGpPWpGaD
Naloxone—CREB1—Signaling Pathways—MTOR—kidney cancer	7.63e-06	4.35e-05	CbGpPWpGaD
Naloxone—OPRD1—Signaling Pathways—MTOR—kidney cancer	7.6e-06	4.33e-05	CbGpPWpGaD
Naloxone—ABCB1—Metabolism—BCHE—kidney cancer	7.6e-06	4.33e-05	CbGpPWpGaD
Naloxone—OPRK1—GPCR downstream signaling—PIK3CA—kidney cancer	7.58e-06	4.32e-05	CbGpPWpGaD
Naloxone—ABCB1—Metabolism—SLC5A5—kidney cancer	7.5e-06	4.28e-05	CbGpPWpGaD
Naloxone—OPRK1—Signaling by GPCR—KRAS—kidney cancer	7.49e-06	4.27e-05	CbGpPWpGaD
Naloxone—CYP3A4—Metabolism—CA9—kidney cancer	7.45e-06	4.25e-05	CbGpPWpGaD
Naloxone—ESR1—Signaling Pathways—HIF1A—kidney cancer	7.4e-06	4.22e-05	CbGpPWpGaD
Naloxone—ESR1—Signaling Pathways—TSC2—kidney cancer	7.38e-06	4.21e-05	CbGpPWpGaD
Naloxone—OPRM1—Signaling Pathways—APC—kidney cancer	7.35e-06	4.19e-05	CbGpPWpGaD
Naloxone—OPRM1—Signaling Pathways—KIT—kidney cancer	7.35e-06	4.19e-05	CbGpPWpGaD
Naloxone—SLCO1A2—Metabolism—PTGS2—kidney cancer	7.32e-06	4.17e-05	CbGpPWpGaD
Naloxone—ABCB1—Metabolism—SLC2A1—kidney cancer	7.25e-06	4.13e-05	CbGpPWpGaD
Naloxone—CREB1—Disease—KRAS—kidney cancer	7.23e-06	4.12e-05	CbGpPWpGaD
Naloxone—CREB1—Immune System—PIK3CA—kidney cancer	7.19e-06	4.1e-05	CbGpPWpGaD
Naloxone—CREB1—Signaling Pathways—CDKN1B—kidney cancer	7.16e-06	4.08e-05	CbGpPWpGaD
Naloxone—OPRD1—Signaling Pathways—CDKN1B—kidney cancer	7.13e-06	4.07e-05	CbGpPWpGaD
Naloxone—ESR1—Signaling Pathways—KDR—kidney cancer	7.08e-06	4.03e-05	CbGpPWpGaD
Naloxone—OPRM1—Signaling by GPCR—MAPK3—kidney cancer	7.04e-06	4.01e-05	CbGpPWpGaD
Naloxone—CYP2C8—Metabolism of lipids and lipoproteins—PTEN—kidney cancer	7.04e-06	4.01e-05	CbGpPWpGaD
Naloxone—CREB1—Signaling Pathways—IL2—kidney cancer	7e-06	3.99e-05	CbGpPWpGaD
Naloxone—ALB—Metabolism of lipids and lipoproteins—PTEN—kidney cancer	7e-06	3.99e-05	CbGpPWpGaD
Naloxone—OPRM1—Signaling Pathways—POMC—kidney cancer	7e-06	3.99e-05	CbGpPWpGaD
Naloxone—OPRD1—Signaling Pathways—IL2—kidney cancer	6.98e-06	3.98e-05	CbGpPWpGaD
Naloxone—ALB—Hemostasis—VEGFA—kidney cancer	6.94e-06	3.96e-05	CbGpPWpGaD
Naloxone—CYP2C8—Metabolism—GSTP1—kidney cancer	6.94e-06	3.95e-05	CbGpPWpGaD
Naloxone—ABCB1—Transmembrane transport of small molecules—RAF1—kidney cancer	6.91e-06	3.94e-05	CbGpPWpGaD
Naloxone—OPRM1—Signaling Pathways—BRAF—kidney cancer	6.91e-06	3.94e-05	CbGpPWpGaD
Naloxone—ALB—Metabolism—GSTP1—kidney cancer	6.9e-06	3.93e-05	CbGpPWpGaD
Naloxone—OPRK1—Signaling by GPCR—PIK3CA—kidney cancer	6.88e-06	3.92e-05	CbGpPWpGaD
Naloxone—CREB1—Signaling Pathways—CCND1—kidney cancer	6.83e-06	3.89e-05	CbGpPWpGaD
Naloxone—OPRK1—Signaling Pathways—RAF1—kidney cancer	6.83e-06	3.89e-05	CbGpPWpGaD
Naloxone—CREB1—Signaling Pathways—JUN—kidney cancer	6.81e-06	3.88e-05	CbGpPWpGaD
Naloxone—OPRD1—Signaling Pathways—CCND1—kidney cancer	6.81e-06	3.88e-05	CbGpPWpGaD
Naloxone—OPRK1—Signaling Pathways—RELA—kidney cancer	6.8e-06	3.87e-05	CbGpPWpGaD
Naloxone—OPRD1—Signaling Pathways—JUN—kidney cancer	6.79e-06	3.87e-05	CbGpPWpGaD
Naloxone—CREB1—Signaling Pathways—CTNNB1—kidney cancer	6.76e-06	3.85e-05	CbGpPWpGaD
Naloxone—OPRK1—Signaling Pathways—ERBB2—kidney cancer	6.75e-06	3.85e-05	CbGpPWpGaD
Naloxone—OPRD1—Signaling Pathways—CTNNB1—kidney cancer	6.74e-06	3.84e-05	CbGpPWpGaD
Naloxone—OPRM1—Signaling by GPCR—MAPK1—kidney cancer	6.7e-06	3.82e-05	CbGpPWpGaD
Naloxone—OPRK1—Signaling Pathways—MTOR—kidney cancer	6.67e-06	3.8e-05	CbGpPWpGaD
Naloxone—CREB1—Disease—PIK3CA—kidney cancer	6.64e-06	3.78e-05	CbGpPWpGaD
Naloxone—CREB1—Signaling Pathways—PTEN—kidney cancer	6.59e-06	3.76e-05	CbGpPWpGaD
Naloxone—ALB—Hemostasis—MAPK3—kidney cancer	6.57e-06	3.74e-05	CbGpPWpGaD
Naloxone—OPRD1—Signaling Pathways—PTEN—kidney cancer	6.57e-06	3.74e-05	CbGpPWpGaD
Naloxone—CYP2C8—Metabolism—ABCB1—kidney cancer	6.57e-06	3.74e-05	CbGpPWpGaD
Naloxone—ALB—Metabolism—ABCB1—kidney cancer	6.53e-06	3.72e-05	CbGpPWpGaD
Naloxone—ESR1—Signaling Pathways—APC—kidney cancer	6.52e-06	3.71e-05	CbGpPWpGaD
Naloxone—ESR1—Signaling Pathways—KIT—kidney cancer	6.52e-06	3.71e-05	CbGpPWpGaD
Naloxone—OPRM1—GPCR downstream signaling—PIK3CA—kidney cancer	6.4e-06	3.65e-05	CbGpPWpGaD
Naloxone—SLCO1A2—Metabolism—PTEN—kidney cancer	6.38e-06	3.64e-05	CbGpPWpGaD
Naloxone—CYP2C8—Metabolism—GSTM1—kidney cancer	6.38e-06	3.63e-05	CbGpPWpGaD
Naloxone—ALB—Metabolism—GSTM1—kidney cancer	6.34e-06	3.61e-05	CbGpPWpGaD
Naloxone—CYP3A4—Metabolism—CRABP1—kidney cancer	6.34e-06	3.61e-05	CbGpPWpGaD
Naloxone—OPRM1—Signaling by GPCR—KRAS—kidney cancer	6.33e-06	3.61e-05	CbGpPWpGaD
Naloxone—OPRK1—Signaling Pathways—CDKN1B—kidney cancer	6.26e-06	3.56e-05	CbGpPWpGaD
Naloxone—ALB—Hemostasis—MAPK1—kidney cancer	6.25e-06	3.56e-05	CbGpPWpGaD
Naloxone—ESR1—Signaling Pathways—POMC—kidney cancer	6.21e-06	3.54e-05	CbGpPWpGaD
Naloxone—ESR1—Signaling Pathways—BRAF—kidney cancer	6.13e-06	3.49e-05	CbGpPWpGaD
Naloxone—OPRK1—Signaling Pathways—IL2—kidney cancer	6.12e-06	3.49e-05	CbGpPWpGaD
Naloxone—ABCB1—Metabolism—GSTP1—kidney cancer	6.05e-06	3.44e-05	CbGpPWpGaD
Naloxone—CYP2C8—Metabolism—CYP1A1—kidney cancer	6.04e-06	3.44e-05	CbGpPWpGaD
Naloxone—ALB—Metabolism—CYP1A1—kidney cancer	6.01e-06	3.42e-05	CbGpPWpGaD
Naloxone—OPRK1—Signaling Pathways—CCND1—kidney cancer	5.97e-06	3.4e-05	CbGpPWpGaD
Naloxone—OPRK1—Signaling Pathways—JUN—kidney cancer	5.96e-06	3.39e-05	CbGpPWpGaD
Naloxone—CREB1—Signaling Pathways—VEGFA—kidney cancer	5.95e-06	3.39e-05	CbGpPWpGaD
Naloxone—OPRD1—Signaling Pathways—VEGFA—kidney cancer	5.93e-06	3.38e-05	CbGpPWpGaD
Naloxone—OPRK1—Signaling Pathways—CTNNB1—kidney cancer	5.91e-06	3.37e-05	CbGpPWpGaD
Naloxone—ALB—Hemostasis—KRAS—kidney cancer	5.9e-06	3.36e-05	CbGpPWpGaD
Naloxone—CYP3A4—Metabolism—ITPR2—kidney cancer	5.89e-06	3.36e-05	CbGpPWpGaD
Naloxone—OPRM1—Signaling by GPCR—PIK3CA—kidney cancer	5.81e-06	3.31e-05	CbGpPWpGaD
Naloxone—OPRM1—Signaling Pathways—RAF1—kidney cancer	5.77e-06	3.29e-05	CbGpPWpGaD
Naloxone—OPRK1—Signaling Pathways—PTEN—kidney cancer	5.76e-06	3.28e-05	CbGpPWpGaD
Naloxone—OPRM1—Signaling Pathways—RELA—kidney cancer	5.74e-06	3.27e-05	CbGpPWpGaD
Naloxone—OPRM1—Signaling Pathways—ERBB2—kidney cancer	5.71e-06	3.25e-05	CbGpPWpGaD
Naloxone—ESR1—Gene Expression—MAPK3—kidney cancer	5.67e-06	3.23e-05	CbGpPWpGaD
Naloxone—OPRM1—Signaling Pathways—MTOR—kidney cancer	5.63e-06	3.21e-05	CbGpPWpGaD
Naloxone—CREB1—Signaling Pathways—MAPK3—kidney cancer	5.63e-06	3.21e-05	CbGpPWpGaD
Naloxone—OPRD1—Signaling Pathways—MAPK3—kidney cancer	5.61e-06	3.2e-05	CbGpPWpGaD
Naloxone—ABCB1—Metabolism—GSTM1—kidney cancer	5.56e-06	3.17e-05	CbGpPWpGaD
Naloxone—ESR1—Gene Expression—MYC—kidney cancer	5.52e-06	3.14e-05	CbGpPWpGaD
Naloxone—CREB1—Signaling Pathways—MYC—kidney cancer	5.48e-06	3.12e-05	CbGpPWpGaD
Naloxone—OPRD1—Signaling Pathways—MYC—kidney cancer	5.46e-06	3.11e-05	CbGpPWpGaD
Naloxone—ALB—Hemostasis—PIK3CA—kidney cancer	5.42e-06	3.09e-05	CbGpPWpGaD
Naloxone—CYP3A4—Metabolism—ACHE—kidney cancer	5.37e-06	3.06e-05	CbGpPWpGaD
Naloxone—CYP3A4—Metabolism—GSTT1—kidney cancer	5.37e-06	3.06e-05	CbGpPWpGaD
Naloxone—CREB1—Signaling Pathways—MAPK1—kidney cancer	5.36e-06	3.05e-05	CbGpPWpGaD
Naloxone—OPRD1—Signaling Pathways—MAPK1—kidney cancer	5.34e-06	3.04e-05	CbGpPWpGaD
Naloxone—OPRM1—Signaling Pathways—CDKN1B—kidney cancer	5.29e-06	3.01e-05	CbGpPWpGaD
Naloxone—ABCB1—Metabolism—CYP1A1—kidney cancer	5.27e-06	3e-05	CbGpPWpGaD
Naloxone—ALB—Hemostasis—TP53—kidney cancer	5.25e-06	2.99e-05	CbGpPWpGaD
Naloxone—OPRK1—Signaling Pathways—VEGFA—kidney cancer	5.2e-06	2.96e-05	CbGpPWpGaD
Naloxone—OPRM1—Signaling Pathways—IL2—kidney cancer	5.17e-06	2.95e-05	CbGpPWpGaD
Naloxone—ESR1—Signaling Pathways—RAF1—kidney cancer	5.12e-06	2.92e-05	CbGpPWpGaD
Naloxone—ESR1—Signaling Pathways—RELA—kidney cancer	5.09e-06	2.9e-05	CbGpPWpGaD
Naloxone—CYP3A4—Metabolism—SCARB1—kidney cancer	5.09e-06	2.9e-05	CbGpPWpGaD
Naloxone—ESR1—Signaling Pathways—ERBB2—kidney cancer	5.06e-06	2.88e-05	CbGpPWpGaD
Naloxone—CREB1—Signaling Pathways—KRAS—kidney cancer	5.06e-06	2.88e-05	CbGpPWpGaD
Naloxone—OPRD1—Signaling Pathways—KRAS—kidney cancer	5.04e-06	2.87e-05	CbGpPWpGaD
Naloxone—OPRM1—Signaling Pathways—CCND1—kidney cancer	5.04e-06	2.87e-05	CbGpPWpGaD
Naloxone—CYP3A4—Metabolism—PTGS1—kidney cancer	5.04e-06	2.87e-05	CbGpPWpGaD
Naloxone—OPRM1—Signaling Pathways—JUN—kidney cancer	5.03e-06	2.87e-05	CbGpPWpGaD
Naloxone—ESR1—Signaling Pathways—MTOR—kidney cancer	5e-06	2.85e-05	CbGpPWpGaD
Naloxone—OPRM1—Signaling Pathways—CTNNB1—kidney cancer	4.99e-06	2.85e-05	CbGpPWpGaD
Naloxone—CYP2C8—Metabolism of lipids and lipoproteins—PIK3CA—kidney cancer	4.97e-06	2.83e-05	CbGpPWpGaD
Naloxone—ALB—Metabolism of lipids and lipoproteins—PIK3CA—kidney cancer	4.94e-06	2.81e-05	CbGpPWpGaD
Naloxone—CYP3A4—Metabolism—PSMD7—kidney cancer	4.94e-06	2.81e-05	CbGpPWpGaD
Naloxone—OPRK1—Signaling Pathways—MAPK3—kidney cancer	4.92e-06	2.8e-05	CbGpPWpGaD
Naloxone—OPRM1—Signaling Pathways—PTEN—kidney cancer	4.87e-06	2.77e-05	CbGpPWpGaD
Naloxone—OPRK1—Signaling Pathways—MYC—kidney cancer	4.79e-06	2.73e-05	CbGpPWpGaD
Naloxone—ESR1—Signaling Pathways—CDKN1B—kidney cancer	4.69e-06	2.67e-05	CbGpPWpGaD
Naloxone—OPRK1—Signaling Pathways—MAPK1—kidney cancer	4.68e-06	2.67e-05	CbGpPWpGaD
Naloxone—CYP3A4—Metabolism—BCHE—kidney cancer	4.68e-06	2.67e-05	CbGpPWpGaD
Naloxone—CREB1—Signaling Pathways—PIK3CA—kidney cancer	4.65e-06	2.65e-05	CbGpPWpGaD
Naloxone—OPRD1—Signaling Pathways—PIK3CA—kidney cancer	4.63e-06	2.64e-05	CbGpPWpGaD
Naloxone—CYP3A4—Metabolism—SLC5A5—kidney cancer	4.62e-06	2.63e-05	CbGpPWpGaD
Naloxone—ESR1—Signaling Pathways—IL2—kidney cancer	4.59e-06	2.61e-05	CbGpPWpGaD
Naloxone—CYP2C8—Metabolism—POMC—kidney cancer	4.51e-06	2.57e-05	CbGpPWpGaD
Naloxone—SLCO1A2—Metabolism—PIK3CA—kidney cancer	4.5e-06	2.56e-05	CbGpPWpGaD
Naloxone—CREB1—Signaling Pathways—TP53—kidney cancer	4.5e-06	2.56e-05	CbGpPWpGaD
Naloxone—OPRD1—Signaling Pathways—TP53—kidney cancer	4.48e-06	2.55e-05	CbGpPWpGaD
Naloxone—ALB—Metabolism—POMC—kidney cancer	4.48e-06	2.55e-05	CbGpPWpGaD
Naloxone—ESR1—Signaling Pathways—CCND1—kidney cancer	4.47e-06	2.55e-05	CbGpPWpGaD
Naloxone—CYP3A4—Metabolism—SLC2A1—kidney cancer	4.47e-06	2.54e-05	CbGpPWpGaD
Naloxone—ESR1—Signaling Pathways—JUN—kidney cancer	4.46e-06	2.54e-05	CbGpPWpGaD
Naloxone—ESR1—Signaling Pathways—CTNNB1—kidney cancer	4.43e-06	2.52e-05	CbGpPWpGaD
Naloxone—OPRK1—Signaling Pathways—KRAS—kidney cancer	4.42e-06	2.52e-05	CbGpPWpGaD
Naloxone—OPRM1—Signaling Pathways—VEGFA—kidney cancer	4.4e-06	2.51e-05	CbGpPWpGaD
Naloxone—ESR1—Signaling Pathways—PTEN—kidney cancer	4.32e-06	2.46e-05	CbGpPWpGaD
Naloxone—OPRM1—Signaling Pathways—MAPK3—kidney cancer	4.16e-06	2.37e-05	CbGpPWpGaD
Naloxone—OPRK1—Signaling Pathways—PIK3CA—kidney cancer	4.06e-06	2.32e-05	CbGpPWpGaD
Naloxone—OPRM1—Signaling Pathways—MYC—kidney cancer	4.05e-06	2.31e-05	CbGpPWpGaD
Naloxone—OPRM1—Signaling Pathways—MAPK1—kidney cancer	3.96e-06	2.26e-05	CbGpPWpGaD
Naloxone—OPRK1—Signaling Pathways—TP53—kidney cancer	3.93e-06	2.24e-05	CbGpPWpGaD
Naloxone—ABCB1—Metabolism—POMC—kidney cancer	3.93e-06	2.24e-05	CbGpPWpGaD
Naloxone—ESR1—Signaling Pathways—VEGFA—kidney cancer	3.9e-06	2.22e-05	CbGpPWpGaD
Naloxone—OPRM1—Signaling Pathways—KRAS—kidney cancer	3.74e-06	2.13e-05	CbGpPWpGaD
Naloxone—CYP3A4—Metabolism—GSTP1—kidney cancer	3.72e-06	2.12e-05	CbGpPWpGaD
Naloxone—ESR1—Signaling Pathways—MAPK3—kidney cancer	3.69e-06	2.1e-05	CbGpPWpGaD
Naloxone—CYP2C8—Metabolism—PTGS2—kidney cancer	3.59e-06	2.05e-05	CbGpPWpGaD
Naloxone—ESR1—Signaling Pathways—MYC—kidney cancer	3.59e-06	2.04e-05	CbGpPWpGaD
Naloxone—ALB—Metabolism—PTGS2—kidney cancer	3.57e-06	2.04e-05	CbGpPWpGaD
Naloxone—CYP3A4—Metabolism—ABCB1—kidney cancer	3.53e-06	2.01e-05	CbGpPWpGaD
Naloxone—ESR1—Signaling Pathways—MAPK1—kidney cancer	3.51e-06	2e-05	CbGpPWpGaD
Naloxone—OPRM1—Signaling Pathways—PIK3CA—kidney cancer	3.43e-06	1.96e-05	CbGpPWpGaD
Naloxone—CYP3A4—Metabolism—GSTM1—kidney cancer	3.42e-06	1.95e-05	CbGpPWpGaD
Naloxone—OPRM1—Signaling Pathways—TP53—kidney cancer	3.32e-06	1.89e-05	CbGpPWpGaD
Naloxone—ESR1—Signaling Pathways—KRAS—kidney cancer	3.31e-06	1.89e-05	CbGpPWpGaD
Naloxone—CYP3A4—Metabolism—CYP1A1—kidney cancer	3.24e-06	1.85e-05	CbGpPWpGaD
Naloxone—CYP2C8—Metabolism—PTEN—kidney cancer	3.14e-06	1.79e-05	CbGpPWpGaD
Naloxone—ABCB1—Metabolism—PTGS2—kidney cancer	3.13e-06	1.78e-05	CbGpPWpGaD
Naloxone—ALB—Metabolism—PTEN—kidney cancer	3.12e-06	1.78e-05	CbGpPWpGaD
Naloxone—ESR1—Signaling Pathways—PIK3CA—kidney cancer	3.05e-06	1.74e-05	CbGpPWpGaD
Naloxone—ESR1—Signaling Pathways—TP53—kidney cancer	2.95e-06	1.68e-05	CbGpPWpGaD
Naloxone—ABCB1—Metabolism—PTEN—kidney cancer	2.73e-06	1.56e-05	CbGpPWpGaD
Naloxone—CYP3A4—Metabolism—POMC—kidney cancer	2.42e-06	1.38e-05	CbGpPWpGaD
Naloxone—CYP2C8—Metabolism—PIK3CA—kidney cancer	2.21e-06	1.26e-05	CbGpPWpGaD
Naloxone—ALB—Metabolism—PIK3CA—kidney cancer	2.2e-06	1.25e-05	CbGpPWpGaD
Naloxone—CYP3A4—Metabolism—PTGS2—kidney cancer	1.93e-06	1.1e-05	CbGpPWpGaD
Naloxone—ABCB1—Metabolism—PIK3CA—kidney cancer	1.93e-06	1.1e-05	CbGpPWpGaD
Naloxone—CYP3A4—Metabolism—PTEN—kidney cancer	1.68e-06	9.59e-06	CbGpPWpGaD
Naloxone—CYP3A4—Metabolism—PIK3CA—kidney cancer	1.19e-06	6.76e-06	CbGpPWpGaD
